Gunagratinib (ICP-192)
-- The latest data of gunagratinib in patients with cholangiocarcinoma
$(CCA)$ was presented at 2023 ASCO-GI3. Gunagratinib showed good efficacy
and safety in previously treated patients with locally advanced or
metastatic CCA harboring FGR2 gene fusions or rearrangements.
Other Corporate Development
-- InnoCare appointed Xin Fu and Jeff Chen as Chief Financial Officer and
Chief Commercial Officer respectively.
-- InnoCare was approved by the Hong Kong Stock Exchange to remove "B"
from the stock code from May 12, 2023. This is another important
milestone in the Company's development.
-- Following the approval for commercial production, InnoCare Guangzhou
quickly launched the manufacturing of orelabrutinib, which is now
available to patients in China. This achievement allows InnoCare to cover
the entire industry chain from in-house research and development to
production.
Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare, said, "We must maintain the entrepreneurial spirit and persist in continuous innovation, focusing on key objectives with high quality growth, so as to make our contributions to patients, partners, and the broader biopharmaceutical industry. We're committed to deepening our focus on original innovation, pushing forward multiple innovative molecules to further strengthen our pipeline; we will accelerate the registrational trials both in China and worldwide, aiming to submit multiple NDAs; we will increase market penetration to achieve our long-term strategy and realize significant sales increases; we will amplify our global presence and push more projects to reach international markets."
To know more about the detailed financial data and business updates of InnoCare 2023 annual results, please log in to https://www.innocarepharma.com/en/investor/home.
Conference Call Information
InnoCare will host a conference call at 8:30 p.m. Beijing time on March 28 in English and at 9:30 p.m. Beijing time in Chinese on March 29, 2024. Participants must register in advance of the conference call. Details are as follows:
For English conference call, please register through the below link:
https://goldmansachs.zoom.us/webinar/register/WN_DYQFyxtGQiC_WaqnlGAMvw#/registration
For Chinese conference call, please register through the below link:
https://net.comein.cn/roadshow/home/199181?institute=zjgs
Forward-looking Statement
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
About InnoCare
InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.
___________________________________
(1) iHealthcareAnalyst, Inc., Oct. 3, 2023
(2) Cancer-free
(3) 2023 ASCO GI Abstract
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328069339/en/
CONTACT: Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com
Investor Relations
86-10-66609999
ir@innocarepharma.com
(END) Dow Jones Newswires
March 28, 2024 09:18 ET (13:18 GMT)
Comments